MarketCapExport financials
Krystal Biotech (KRYS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Krystal Biotech Balance Sheet 2025-2011 | KRYS
Brief overview of Krystal Biotech's balance sheet strength
The review uses the five latest available annual reports between 2021 and 2025.
Assets reached $1.3 billion, compared with $626.3 million at the beginning. Growth of +113% and CAGR near 20.8% show active expansion.
Funding shifted toward liabilities: they gained +249.1%, compared with +113% for assets.
The equity ratio reached 91.4% from 94.8%. A high capital share reduces dependence on liabilities.
Net debt moved below zero to -$487 million, reflecting surplus cash over debt.
Cash equals 37.2% of the balance sheet, compared with 54.5% five periods ago. This is the readily available cushion.
By the end of the period, accumulated earnings were $24.2 million; the change from the start was +117.2%.
Balance sheet takeaway
Krystal Biotech has a solid balance sheet cushion. Capital and liquidity support development without excessive reliance on debt.
Annual Balance Sheet Krystal Biotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-487 M | -338 M | -350 M | -153 M | -333 M | -260 M | -184 M | -104 M | -49.6 M | -80 K | - | - | - | - | - |
Long Term Debt |
7.57 M | 6.04 M | 6.62 M | 7.37 M | 6.98 M | 3.31 M | - | - | - | 1.84 M | - | - | - | - | - |
Long Term Debt Current |
1.77 M | 1.22 M | 1.47 M | 1.56 M | 1.04 M | 5.11 M | 480 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
11.3 M | 7.46 M | 6.62 M | 7.37 M | 6.98 M | 3.31 M | 2.78 M | 294 K | - | 1.85 M | - | - | - | - | - |
Total Current Liabilities |
103 M | 102 M | 33.1 M | 28.8 M | 25.7 M | 15.5 M | 3.33 M | - | 640 K | - | - | - | - | - | - |
Total Liabilities |
114 M | 109 M | 39.7 M | 36.2 M | 32.7 M | 18.8 M | 6.11 M | 2.89 M | 640 K | 1.89 M | - | - | - | - | - |
Retained Earnings |
24.2 M | -181 M | -270 M | -281 M | -141 M | -71.2 M | -39 M | -20 M | -9.07 M | -1.15 M | - | - | - | - | - |
Total Assets |
1.33 B | 1.06 B | 818 M | 558 M | 626 M | 311 M | 209 M | 116 M | 50.1 M | 2.18 M | - | - | - | - | - |
Cash and Cash Equivalents |
496 M | 345 M | 358 M | 162 M | 341 M | 268 M | 188 M | 104 M | 49.6 M | 1.92 M | - | - | - | - | - |
Book Value |
1.22 B | 946 M | 779 M | 522 M | 594 M | 292 M | 203 M | 113 M | 49.5 M | 289 K | - | - | - | - | - |
Total Shareholders Equity |
1.22 B | 946 M | 779 M | 522 M | 594 M | 292 M | 203 M | 113 M | 49.5 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Krystal Biotech
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
6.77 M | 7.04 M | 7.31 M | 7.57 M | 7.81 M | 8.06 M | 8.3 M | 6.04 M | 6.18 M | 6.33 M | 6.46 M | 6.62 M | 6.82 M | 7.01 M | 7.01 M | 7.37 M | 7.58 M | 7.72 M | 7.88 M | 7.37 M | 7.08 M | 6.9 M | 3.22 M | 3.31 M | 2.53 M | 2.62 M | 3.31 M | 2.78 M | 2.86 M | 2.93 M | 2.98 M | - | - | - | - | - | - | 4.25 M | 4.25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
8.33 M | 14.1 M | 12.4 M | 11.3 M | 11 M | 10.9 M | 10.3 M | 7.46 M | 6.94 M | 6.91 M | 6.46 M | 6.62 M | 6.82 M | - | 7.01 M | - | 7.58 M | 7.72 M | 7.88 M | 7.37 M | 7.08 M | 6.9 M | 3.22 M | 3.31 M | 2.53 M | 2.62 M | 2.7 M | 2.78 M | 2.86 M | 2.93 M | 2.98 M | - | 245 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
150 M | 142 M | 120 M | 114 M | 102 M | 97.7 M | 89.7 M | 109 M | 96.5 M | 78.8 M | 54.1 M | 39.7 M | 34.4 M | 30.9 M | 30.9 M | 36.2 M | 35.6 M | 42.1 M | 68.3 M | 36.2 M | 42.9 M | 25 M | 12.4 M | 18.8 M | 9.73 M | 8.45 M | 6.76 M | 6.11 M | 6.59 M | 6.87 M | 6.22 M | 2.89 M | 2.16 M | 759 K | 452 K | 640 K | 2.48 M | 640 K | 640 K | 1.89 M | 1.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
198 M | 135 M | 80.1 M | 24.2 M | -27.2 M | -107 M | -145 M | -181 M | -226 M | -253 M | -269 M | -270 M | -279 M | -359 M | -359 M | -281 M | -249 M | -219 M | -191 M | -281 M | -119 M | -103 M | -87 M | -71.2 M | -60.8 M | -51.2 M | -44.4 M | -39 M | -33.7 M | -29.4 M | -24.1 M | -20 M | -16.3 M | -13.5 M | -11.2 M | -9.07 M | -7.68 M | -9.07 M | -9.07 M | -1.15 M | -1.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
1.59 B | 1.5 B | 1.4 B | 1.33 B | 1.24 B | 1.14 B | 1.07 B | 1.06 B | 982 M | 918 M | 853 M | 818 M | 790 M | 684 M | 684 M | 558 M | 576 M | 601 M | 617 M | 558 M | 451 M | 444 M | 443 M | 311 M | 311 M | 318 M | 205 M | 209 M | 214 M | 205 M | 116 M | 116 M | 54.5 M | 46 M | 47.9 M | 50.1 M | 52.7 M | 50.1 M | 50.1 M | 2.18 M | 2.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
463 M | 428 M | 501 M | 496 M | 393 M | 354 M | 309 M | 345 M | 374 M | 346 M | 359 M | 358 M | 373 M | 276 M | 276 M | 162 M | 186 M | 219 M | 269 M | 162 M | 287 M | 330 M | 402 M | 268 M | 282 M | 292 M | 180 M | 188 M | 195 M | 187 M | 98 M | 104 M | 46.7 M | 41.8 M | 47.2 M | 49.6 M | 49.6 M | 49.6 M | 49.6 M | 1.92 M | 1.92 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.44 B | 1.36 B | 1.28 B | 1.22 B | 1.14 B | 1.04 B | 985 M | 946 M | 886 M | 839 M | 799 M | 779 M | 756 M | 653 M | 653 M | 522 M | 541 M | 559 M | 549 M | 522 M | 408 M | 419 M | 431 M | 292 M | 302 M | 310 M | 198 M | 203 M | 208 M | 198 M | 109 M | 113 M | 52.3 M | 45.3 M | 47.4 M | 49.5 M | 50.2 M | 49.5 M | 49.5 M | 289 K | 289 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.44 B | 1.36 B | 1.28 B | 1.22 B | 1.14 B | 1.04 B | 985 M | 946 M | 886 M | 839 M | 799 M | 779 M | 756 M | 653 M | 653 M | 522 M | 541 M | 559 M | 549 M | 522 M | 408 M | 419 M | 431 M | 292 M | 302 M | 310 M | 198 M | 203 M | 208 M | 198 M | 109 M | 113 M | 52.3 M | 45.3 M | 47.4 M | 49.5 M | 49.5 M | 49.5 M | 49.5 M | 289 K | 289 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Krystal Biotech, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
China
Canada
Israel
Britain
Cayman-islands
Danmark
